ReviewCurrent opinion in virology2022
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world.
Review in Current opinion in virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Review
- Characterization ofMicrobiology spectrum · 2026Article
- Regenerative Microbiology: Harnessing Bacterial Antagonism and Spatiotemporal Signaling for Diabetic Wound Repair.Smart medicine · 2026Review
- Characterization and comparative genomic analysis of a novel bacteriophage against an extremely drug-resistantMicrobiology spectrum · 2026Article
- Novel Silviavirus phages with broad-host-range activity against methicillin resistant Staphylococcus aureus from seafood: comprehending the phenotypic and genotypic variability.Folia microbiologica · 2026Article
- Isolation and Genomic Characterization of a Lytic Bacteriophage Against Multidrug-ResistantViruses · 2026Article
- Efficacy of lytic bacteriophages isolated from sewage-treatment plants in Mbarara district, Uganda against ciprofloxacin-resistant Salmonella Typhi in a mice infection model.BMC infectious diseases · 2026Article
- Phages for One Health: regulatory and product life cycle considerations.Microbiology (Reading, England) · 2026Review
- Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review.Infectious diseases and therapy · 2026Review
- Rolling outMicrobial genomics · 2026Article
- Characterization, genomic insights and anti-biofilm potential of phage vB_PaeM_PKMS3, a lytic Pbunavirus capable of infecting clinical Pseudomonas aeruginosa isolates.Antonie van Leeuwenhoek · 2026Article
- Review
- Article
- Isolation and characterization of a lytic phage and its efficacy against multi-drug resistant strains of pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Phage-encoded small RNA hijacks host replication machinery to support the phage lytic cycle.Molecular cell · 2025Article
- Eliminating the type I restriction endonuclease fromMicrobiology (Reading, England) · 2025Article
- The future of phage therapy in the USA.Trends in molecular medicine · 2025Review
- Metagenome-inspired libraries to engineer phage M13 for targeted killing of Gram-negative bacterial species.Nucleic acids research · 2025Article
- Bacteria-phage infection network structure and genomic defence system content predict efficacy of a phage therapy cocktail againstPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower and middle-income countries seldom develop vaccines and therapeutics for their own populations and are dependent on supplies from industrialized countries, which are often hampered by financial or supply chain limitations. This has resulted in major delays in delivery with significant loss of life, as seen with the coronavirus pandemic. Since the vast majority of deaths from the antimicrobial resistance crisis are expected to occur in developing countries, there is an urgent need for in-country production of antibacterial therapies such as phages. Nationally controlled phage banks might provide such a solution since locally developed phage therapies tailored to endemic bacterial strains could offer cost-effective antibiotic alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.